Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2164)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 26.04.24 23:20:55 von
neuester Beitrag 26.04.24 23:20:55 von
Beiträge: 22.815
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 31
Gesamt: 1.231.746
Gesamt: 1.231.746
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
3,8085
EUR
+3,58 %
+0,1315 EUR
Letzter Kurs 26.04.24 Tradegate
Neuigkeiten
20.04.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,8660 | +44,27 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Why Novavax Stock Spiked Today
Motley Fool March 1, 2018
What happened
Shares of the clinical-stage vaccine maker Novavax (NASDAQ: NVAX) rose by as much as 27.6% today on over three times the average daily trading volume. Although the biotech's stock has cooled off in the interim, Novavax's shares are still up by a healthy 7% as of 2:44 p.m. EST.
The catalyst? Before the opening bell, the company reported positive top-line results for its experimental flu vaccine, NanoFlu, in a combined phase 1/2 trial in older adults. The headline item is that NanoFlu reportedly outperformed Sanofi's market-leading Fluzone High-Dose by generating higher hemagglutination inhibition (HAI) antibody responses against both the H1N1 and H3N2 influenza strains.
So what
After an unusually severe flu season in which Sanofi and other vaccine makers were largely unable to adequately control the outbreak, the multibillion dollar flu vaccine market is arguably ripe for the picking by a newcomer like Novavax's NanoFlu.
Now what
According to its press release, Novavax said it plans on initiating another midstage trial for NanoFlu by the third quarter of this year. That's the good news.
The bad news is that company is going to have to raise a significant sum of capital soon in order to carry out another trial for NanoFlu and advance its other clinical candidates at the same time. Novavax, after all, only had around $172 million in cash remaining at the end of the last quarter, but an annual burn rate of about $168 million. With additional trials in the works, Novavax's burn rate probably won't taper off anytime soon.
All told, Novavax's initial NanoFlu data are certainly intriguing from a value proposition standpoint. But the company arguably needs to address its long-term financial needs. Until then, this small-cap biotech stock will continue to be an exceptionally volatile equity.
https://finance.yahoo.com/news/why-novavax-stock-spiked-toda…
Motley Fool March 1, 2018
What happened
Shares of the clinical-stage vaccine maker Novavax (NASDAQ: NVAX) rose by as much as 27.6% today on over three times the average daily trading volume. Although the biotech's stock has cooled off in the interim, Novavax's shares are still up by a healthy 7% as of 2:44 p.m. EST.
The catalyst? Before the opening bell, the company reported positive top-line results for its experimental flu vaccine, NanoFlu, in a combined phase 1/2 trial in older adults. The headline item is that NanoFlu reportedly outperformed Sanofi's market-leading Fluzone High-Dose by generating higher hemagglutination inhibition (HAI) antibody responses against both the H1N1 and H3N2 influenza strains.
So what
After an unusually severe flu season in which Sanofi and other vaccine makers were largely unable to adequately control the outbreak, the multibillion dollar flu vaccine market is arguably ripe for the picking by a newcomer like Novavax's NanoFlu.
Now what
According to its press release, Novavax said it plans on initiating another midstage trial for NanoFlu by the third quarter of this year. That's the good news.
The bad news is that company is going to have to raise a significant sum of capital soon in order to carry out another trial for NanoFlu and advance its other clinical candidates at the same time. Novavax, after all, only had around $172 million in cash remaining at the end of the last quarter, but an annual burn rate of about $168 million. With additional trials in the works, Novavax's burn rate probably won't taper off anytime soon.
All told, Novavax's initial NanoFlu data are certainly intriguing from a value proposition standpoint. But the company arguably needs to address its long-term financial needs. Until then, this small-cap biotech stock will continue to be an exceptionally volatile equity.
https://finance.yahoo.com/news/why-novavax-stock-spiked-toda…
Antwort auf Beitrag Nr.: 57.159.375 von Ginelli83 am 01.03.18 15:13:492,95$, ich hoffe du gewinnst
Antwort auf Beitrag Nr.: 57.159.333 von DasTier666 am 01.03.18 15:10:31Schließen bei 3,10$, mein Tipp 💪🏻
gestern nachbörslich ca. 2 Mio gehandelt und heut schon ca. 1,8 Mio
vorbörslich 30%, 3$ voraus
vorbörslich 30%, 3$ voraus
Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
https://ih.advfn.com/p.php?pid=nmona&article=76829289
na dann, auf geht's
https://ih.advfn.com/p.php?pid=nmona&article=76829289
na dann, auf geht's
Trading Spotlight
Antwort auf Beitrag Nr.: 57.069.492 von DasTier666 am 20.02.18 13:45:55Habe es eben gesehen von knapp 6$ auf 2$, puuh krass
Antwort auf Beitrag Nr.: 57.069.474 von DasTier666 am 20.02.18 13:43:56ich glaub der Chart wird nicht geladen, ich meinte Tetraphase.
Antwort auf Beitrag Nr.: 57.069.354 von Ginelli83 am 20.02.18 13:33:55
Da lief eine Phase III nicht so gut.
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Da lief eine Phase III nicht so gut.
Antwort auf Beitrag Nr.: 57.045.525 von Edison09 am 16.02.18 16:58:20Einige US Jungs (Yahoo, InvestorVillage) vermuten für heut Nachrichten. Mal schauen. Ich hoffe, dass ich diesmal mehr Glück habe als bei TTPH.
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |